# Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

> **NCT05230550** · — · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 200 (estimated)

## Conditions studied

- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** Somapacitan

## Key facts

- **NCT ID:** NCT05230550
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05230550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05230550, "Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05230550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*